Perceptive Advisors LLC Buys New Position in Keryx Biopharmaceuticals (KERX)

Perceptive Advisors LLC bought a new stake in shares of Keryx Biopharmaceuticals (NASDAQ:KERX) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 83,386 shares of the biopharmaceutical company’s stock, valued at approximately $592,000. Perceptive Advisors LLC owned approximately 0.07% of Keryx Biopharmaceuticals at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in KERX. Russell Investments Group Ltd. grew its stake in Keryx Biopharmaceuticals by 742.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 754,631 shares of the biopharmaceutical company’s stock valued at $5,358,000 after acquiring an additional 665,069 shares in the last quarter. State Street Corp grew its stake in shares of Keryx Biopharmaceuticals by 20.1% in the 1st quarter. State Street Corp now owns 3,479,370 shares of the biopharmaceutical company’s stock valued at $21,432,000 after buying an additional 582,624 shares in the last quarter. Monarch Partners Asset Management LLC bought a new stake in shares of Keryx Biopharmaceuticals in the 2nd quarter valued at approximately $3,059,000. Chicago Equity Partners LLC bought a new stake in shares of Keryx Biopharmaceuticals in the 2nd quarter valued at approximately $2,756,000. Finally, Vanguard Group Inc. grew its stake in shares of Keryx Biopharmaceuticals by 5.1% in the 2nd quarter. Vanguard Group Inc. now owns 7,198,269 shares of the biopharmaceutical company’s stock valued at $52,043,000 after buying an additional 349,521 shares in the last quarter. 64.83% of the stock is currently owned by institutional investors.

Shares of Keryx Biopharmaceuticals (KERX) opened at $4.74 on Monday. Keryx Biopharmaceuticals has a 12 month low of $4.33 and a 12 month high of $8.38. The company has a current ratio of 4.46, a quick ratio of 3.76 and a debt-to-equity ratio of 13.95.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.03). The firm had revenue of $15.00 million during the quarter, compared to the consensus estimate of $18.88 million. Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The company’s quarterly revenue was up 138.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.39) EPS. equities research analysts anticipate that Keryx Biopharmaceuticals will post -1.36 EPS for the current fiscal year.

Several equities research analysts recently commented on the company. Zacks Investment Research cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 8th. ValuEngine cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st. BidaskClub raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Finally, Stifel Nicolaus lowered their price target on Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company. Keryx Biopharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $7.35.

TRADEMARK VIOLATION WARNING: “Perceptive Advisors LLC Buys New Position in Keryx Biopharmaceuticals (KERX)” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.chaffeybreeze.com/2017/12/11/perceptive-advisors-llc-buys-new-position-in-keryx-biopharmaceuticals-kerx.html.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Want to see what other hedge funds are holding KERX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keryx Biopharmaceuticals (NASDAQ:KERX).

Institutional Ownership by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply